drugset / Trial / NCT03894150
A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I dose escalation study designed to define the maximum tolerable dose(MDT), the safety profile, pharmacokinetic parameters, immunogenicity and anti-tumor activity of F0002-ADC in Chinese patients with relapsed/refractory CD30-positive hematologic malignancies.
Timeline
- Start
- 2019-04-11
- Primary completion
- 2020-07-01
- Completion
- 2024-03-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F0002-ADC | Unknown | 0.3 mg/kg | — |
| Subject | F0002-ADC | Unknown | 4.8 mg/kg | — |